These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 15452399

  • 21. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
    Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA.
    Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
    [Abstract] [Full Text] [Related]

  • 22. In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I, Kucukercan M, Ceran N.
    Chemotherapy; 2003 Dec; 49(6):294-7. PubMed ID: 14671429
    [Abstract] [Full Text] [Related]

  • 23. Comparison of antimicrobial resistance of Acinetobacter baumannii clinical isolates from Shanghai and Hong Kong.
    Ling TK, Ying CM, Lee CC, Liu ZK.
    Med Princ Pract; 2005 Dec; 14(5):338-41. PubMed ID: 16103700
    [Abstract] [Full Text] [Related]

  • 24. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa.
    Pruekprasert P, Tunyapanit W.
    Southeast Asian J Trop Med Public Health; 2005 Sep; 36(5):1239-42. PubMed ID: 16438151
    [Abstract] [Full Text] [Related]

  • 25. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
    Alişkan H, Colakoğlu S, Turunç T, Demiroğlu YZ, Erdoğan F, Akin S, Arslan H.
    Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. In vitro efficacy of levofloxacin alone or in combination tested against multi-resistant Pseudomonas aeruginosa strains.
    Flynn CM, Johnson DM, Jones RN.
    J Chemother; 1996 Dec; 8(6):411-5. PubMed ID: 8981179
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Activity of amikacin, ertapenem, ciprofloxacin and levofloxacin alone and in combination against resistant nosocomial pathogens by time-kill.
    Hosgor-Limoncu M, Ermertcan S, Tasli H, Yurtman AN.
    West Indian Med J; 2008 Mar; 57(2):106-11. PubMed ID: 19565951
    [Abstract] [Full Text] [Related]

  • 37. Antimicrobial susceptibility of multidrug-resistant Pseudomonas aeruginosa isolated from drinking water and hospitalized patients in Jordan.
    Tarazi YH, Abu-Basha E, Ismail ZB, Al-Jawasreh SI.
    Acta Trop; 2021 May; 217():105859. PubMed ID: 33582141
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001.
    Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF.
    Antimicrob Agents Chemother; 2003 May; 47(5):1681-8. PubMed ID: 12709340
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.